PTM Biolabs, a Chinese firm that develops proteomics technology to help diagnose and treat human diseases, has raised 530 million yuan ($80 million) in a Series B round of financing led by Beijing-based investment firm IDG Capital, per its announcement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
